<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05032287</url>
  </required_header>
  <id_info>
    <org_study_id>MET SWL</org_study_id>
    <nct_id>NCT05032287</nct_id>
  </id_info>
  <brief_title>Medical Expulsive Therapy Post-SWL For Renal Stones</brief_title>
  <official_title>Medical Expulsive Therapy Post-SWL For Renal Stones. A Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and stone free rate of placebo versus tamsulosin as medical&#xD;
      expulsive therapy post-SWL in patients with renal stone less than 20 mm&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Actual">May 1, 2020</completion_date>
  <primary_completion_date type="Actual">May 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stone free rate defined as patient free of any stone residual</measure>
    <time_frame>at 3 months</time_frame>
    <description>assessed by Non-contrast Computed Tomography of Urinary Tract (NCCT-UT)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">235</enrollment>
  <condition>Urologic Diseases</condition>
  <condition>Urolithiasis</condition>
  <condition>Stone, Kidney</condition>
  <arm_group>
    <arm_group_label>tamsulosin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tamsulosin 0.4 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placeb</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin</intervention_name>
    <description>Tamsulosin 0.4 mg once daily</description>
    <arm_group_label>tamsulosin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo once daily</description>
    <arm_group_label>Placeb</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Renal stone ≤ 20 mm.&#xD;
&#xD;
          -  Lower calyceal stone ≤ 15 mm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women with known or suspected pregnancy or breastfeeding.&#xD;
&#xD;
          -  History of alpa-blockers (more than 7 days prior to study participation)&#xD;
&#xD;
          -  History of ureteral stricture&#xD;
&#xD;
          -  Multiple (that is more than 2) stones&#xD;
&#xD;
          -  Stone in solitary kidney (either anatomically or functionally).&#xD;
&#xD;
          -  Presence of urinary sepsis.&#xD;
&#xD;
          -  Estimated glomerular filtration rate &lt; 30 ml/min&#xD;
&#xD;
          -  Contraindication or allergy to tamsulosin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Urology and Nephrology Center</name>
      <address>
        <city>Mansourah</city>
        <state>Aldakahlia</state>
        <zip>35516</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 25, 2021</study_first_submitted>
  <study_first_submitted_qc>August 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urolithiasis</mesh_term>
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
    <mesh_term>Urologic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

